Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma

Research output: Contribution to journalArticle

Bibtex

@article{7191f91f0a9d4d998ee3597450065620,
title = "Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma",
abstract = "Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. Patient summary: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment na{\"i}ve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.",
keywords = "Cabozantinib, Guidelines, Immune checkpoint inhibitors, Ipilimumab, Metastatic, Nivolumab, Pazopanib, Renal cell carcinoma, Sunitinib",
author = "Laurence Albiges and Tom Powles and Michael Staehler and Karim Bensalah and Giles, {Rachel H.} and Milan Hora and Kuczyk, {Markus A.} and Lam, {Thomas B.} and B{\"o}rje Ljungberg and Lorenzo Marconi and Merseburger, {Axel S.} and Alessandro Volpe and Yasmin Abu-Ghanem and Saeed Dabestani and Sergio Fern{\'a}ndez-Pello and Fabian Hofmann and Teele Kuusk and Rana Tahbaz and Axel Bex",
year = "2019",
doi = "10.1016/j.eururo.2019.05.022",
language = "English",
volume = "76",
pages = "151--156",
journal = "European Urology",
issn = "1873-7560",
publisher = "Elsevier",
number = "2",

}